|
1
|
Yoshida M, Seiki M, Yamaguchi K and
Takatsuki K: Monoclonal integration of human T-cell leukemia
provirus in all primary tumors of adult T-cell leukemia suggests
causative role of human T-cell leukemia virus in the disease. Proc
Natl Acad Sci USA. 81:pp. 2534–2537. 1984; View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vose J, Armitage J and Weisenburger D;
International T-Cell Lymphoma Project, : International peripheral
T-cell and natural killer/T-cell lymphoma study: Pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ishida T, Hishizawa M, Kato K, Tanosaki R,
Fukuda T, Taniguchi S, Eto T, Takatsuka Y, Miyazaki Y, Moriuchi Y,
et al: Allogeneic hematopoietic stem cell transplantation for adult
T-cell leukemia-lymphoma with special emphasis on preconditioning
regimen: A nationwide retrospective study. Blood. 120:1734–1741.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosich L, Saborit-Villarroya I,
López-Guerra M, Xargay-Torrent S, Montraveta A, Aymerich M,
Villamor N, Campo E, Pérez-Galán P, Roué G and Colomer D: The
phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes
resistance signals derived from microenvironment by regulating the
Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
Haematologica. 98:1739–1747. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakahata S, Ichikawa T, Maneesaay P, Saito
Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M,
Kitabayashi I, et al: Loss of NDRG2 expression activates PI3K-AKT
signalling via PTEN phosphorylation in ATLL and other cancers. Nat
Commun. 5:33932014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rodon J, Dienstmann R, Serra V and
Tabernero J: Development of PI3K inhibitors: Lessons learned from
early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li
H, Lin H, Lan Y, Liu Z, He J, et al: Novel phosphatidylinositol
3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells
and shows synergistic anti-myeloma activity with dexamethasone. J
Mol Med (Berl). 90:695–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ren H, Zhao L, Li Y, Yue P, Deng X,
Owonikoko TK, Chen M, Khuri FR and Sun SY: The PI3 kinase inhibitor
NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation,
contributing to induction of apoptosis and enhancement of
TRAIL-induced apoptosis. Cancer Lett. 338:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zang C, Eucker J, Liu H, Coordes A, Lenarz
M, Possinger K and Scholz CW: Inhibition of pan-class I
phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks
proliferation and induces cell death in diffuse large B-cell
lymphoma. Leuk Lymphoma. 55:425–434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rodon J, Braña I, Siu LL, De Jonge MJ,
Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, et
al: Phase I dose-escalation and -expansion study of buparlisib
(BKM120), an oral pan-Class I PI3K inhibitor, in patients with
advanced solid tumors. Invest New Drugs. 32:670–681. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhat M, Robichaud N, Hulea L, Sonenberg N,
Pelletier J and Topisirovic I: Targeting the translation machinery
in cancer. Nat Rev Drug Discov. 14:261–278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Reilly KE, Rojo F, She QB, Solit D,
Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al:
mTOR inhibition induces upstream receptor tyrosine kinase signaling
and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhatt AP, Bhende PM, Sin SH, Roy D,
Dittmer DP and Damania B: Dual inhibition of PI3K and mTOR inhibits
autocrine and paracrine proliferative loops in
PI3K/Akt/mTOR-addicted lymphomas. Blood. 115:4455–4463. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maira SM, Stauffer F, Brueggen J, Furet P,
Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker
K, et al: Identification and characterization of NVP-BEZ235, a new
orally available dual phosphatidylinositol 3-kinase/mammalian
target of rapamycin inhibitor with potent in vivo antitumor
activity. Mol Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bhende PM, Park SI, Lim MS, Dittmer DP and
Damania B: The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious
against follicular lymphoma. Leukemia. 24:1781–1784. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shortt J, Martin BP, Newbold A, Hannan KM,
Devlin JR, Baker AJ, Ralli R, Cullinane C, Schmitt CA, Reimann M,
et al: Combined inhibition of PI3K-related DNA damage response
kinases and mTORC1 induces apoptosis in MYC-driven B-cell
lymphomas. Blood. 121:2964–2974. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiarini F, Grimaldi C, Ricci F, Tazzari
PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E,
Melchionda F, Pession A, et al: Activity of the novel dual
phosphatidylinositol 3-kinase/mammalian target of rapamycin
inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Cancer Res. 70:8097–8107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishiyama M, Miyazono Y, Sasamoto K, Ohkura
Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt
as a chromogenic indicator for NADH as well as cell viability.
Talanta. 44:1299–1305. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang C, Ao Z, Seth A and Schlossman SF: A
mitochondrial membrane protein defined by a novel monoclonal
antibody is preferentially detected in apoptotic cells. J Immunol.
157:3980–3987. 1996.PubMed/NCBI
|
|
21
|
Tomayko MM and Reynolds CP: Determination
of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother
Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikezoe T, Nishioka C, Bandobashi K, Yang
Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP and Taguchi H:
Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and
rapamycin induces growth arrest of adult T-cell leukemia cells.
Leuk Res. 31:673–682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weinberg RA: The retinoblastoma protein
and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kamihira S, Atogami S, Sohda H, Momita S,
Yamada Y and Tomonaga M: Significance of soluble interleukin-2
receptor levels for evaluation of the progression of adult T-cell
leukemia. Cancer. 73:2753–2758. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishioka C, Takemoto S, Kataoka S,
Yamanaka S, Moriki T, Shoda M, Watanabe T and Taguchi H: Serum
level of soluble CD30 correlates with the aggressiveness of adult
T-cell leukemia/lymphoma. Cancer Sci. 96:810–815. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martelli AM, Chiarini F, Evangelisti C,
Cappellini A, Buontempo F, Bressanin D, Fini M and McCubrey JA: Two
hits are better than one: Targeting both phosphatidylinositol
3-kinase and mammalian target of rapamycin as a therapeutic
strategy for acute leukemia treatment. Oncotarget. 3:371–394. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Z, Wu Y, Zhou X, Qian J, Zhu W, Shu
Y and Liu P: Clinical efficacy of mTOR inhibitors in solid tumors:
A systematic review. Future Oncol. 11:1687–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
